VCEL Vericel Corporation

2.65
+0  (2%)
Previous Close 2.60
Open 2.60
Price To book 0.00
Market Cap 86.72M
Shares 32,723,000
Volume 83,483
Short Ratio 3.22
Av. Daily Volume 365,373

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b topline data released March 2016. Full data released April 2016
ixmyelocel-T
Stem cells - Dilated Cardiomyopathy
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
MACI
Focal chondral cartilage defects in the knee.

Latest News

  1. Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
  2. ETFs with exposure to Vericel Corp. : April 7, 2017
  3. Vericel to Present at the 16th Annual Needham Healthcare Conference
  4. ETFs with exposure to Vericel Corp. : March 27, 2017
  5. Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
  6. Vericel Corp. :VCEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  7. Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
  8. Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
  9. Vericel to Present at Multiple Upcoming Investor Conferences
  10. Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks
  11. Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
  12. Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
  13. ETFs with exposure to Vericel Corp. : January 19, 2017
  14. Is Rentech, Inc. (RTK) A Good Stock To Buy According To Hedge Funds?
  15. ETFs with exposure to Vericel Corp. : December 16, 2016
  16. Vericel Wins on Key FDA Approval